Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $20,535,255.90 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 220,170 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $93.27, for a total value of $20,535,255.90. Following the completion of the sale, the chief executive officer owned 780,037 shares of the company’s stock, valued at $72,754,050.99. This represents a 22.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Trading Down 8.1%

KNSA opened at $88.34 on Friday. The stock has a market cap of $6.89 billion, a PE ratio of 67.95 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 1 year low of $37.02 and a 1 year high of $98.48. The stock’s 50 day simple moving average is $80.18 and its 200-day simple moving average is $61.10.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The business had revenue of $285.97 million during the quarter, compared to analyst estimates of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. Equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently modified their holdings of KNSA. Lisanti Capital Growth LLC grew its stake in Kiniksa Pharmaceuticals International by 48.0% during the third quarter. Lisanti Capital Growth LLC now owns 129,250 shares of the company’s stock worth $9,643,000 after buying an additional 41,945 shares during the last quarter. Jacobi Capital Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth approximately $48,000. Ethic Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth approximately $726,000. Pictet Asset Management Holding SA raised its stake in shares of Kiniksa Pharmaceuticals International by 41.3% in the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock valued at $64,182,000 after acquiring an additional 251,578 shares during the last quarter. Finally, AlphaCentric Advisors LLC bought a new position in shares of Kiniksa Pharmaceuticals International in the third quarter valued at approximately $596,000. Institutional investors own 53.95% of the company’s stock.

Analysts Set New Price Targets

KNSA has been the subject of a number of recent research reports. The Goldman Sachs Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. JPMorgan Chase & Co. lifted their target price on shares of Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Finally, Canaccord Genuity Group upped their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $100.57.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.